HIV drug resistance assessment in the Western Pacific Region. A systematic review

AIDS Reviews

Volumn 13, Issue 4, 2011, Pages 214-226

  Yu, Dongbao ^a   Sutherland, Donald ^b   Ghidinelli, Massimo ^a   Jordan, Michael R ^a,c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Consultant Global Public Health ^*  (Canada)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; HIV; Western Pacific

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL RESISTANCE; CAMBODIA; CHINA; DRUG QUALITY; DRUG SURVEILLANCE PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; PREVALENCE; REVIEW; SYSTEMATIC REVIEW; VIET NAM; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PUBLIC HEALTH;

EID: 80655148154     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. WHO/UNICEF/UNAIDS. Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report 2010. Geneva, 2010.
2. Srikantiah P, Ghidinelli M, Bachni D, et al. Scale up of national antiretroviral therapy programs: progresses and challenges. AIDS. 2010;14(Suppl 3):S62-71.
3. Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis. 2008;47:825-33.
4. WHO/WPRO. ARV use survey (unpublished data). Manila., 2010.
5. Richman D, Morton S, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393-401. (Pubitemid 38925131)
6. Jordan M. HIV drug resistance. IAS 2010, Vienna, Austria.
7. Pasquet A, Messou E, Gabillard D, et al. Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One. 2010;5:e13414.
8. Bennett D, Bertagnolio S, Sutherland D, Gilks C. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13(Suppl 2):1-13. (Pubitemid 352019085)
9. Bennett D, Myatt M, Bertagnolio S, Sutherland D, Gilks C. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13(Suppl 2):25-36. (Pubitemid 352019087)
10. Nicastri E, Sarmati L, d'Ettorre G, et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol. 2003;69:1-6. (Pubitemid 35403647)
11. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr. 2004;37:1570-3. (Pubitemid 39658194)
12. Little S, Frost S, Wong J, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol. 2008;82:5510-8. (Pubitemid 351705258)
13. Johnson J, Li J, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med. 2008;5:e158.
14. Palmer S, Boltz V, Maldarelli F, et al. Selection and persistence of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS. 2006;20:701-10. (Pubitemid 43884297)
15. Bennett D, Camacho R, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4:e4724.
16. Rhee S, Gonzales M, Kantor R, Betts B, Ravela J, Shafer R. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31:298-303. (Pubitemid 36150389)
17. Shafer R. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194(Suppl 1):S51-8. (Pubitemid 44420873)
18. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2008;16:138-45.
19. Morgan D, Mahe C, Mayanja B, Okongo J, Lubega R, Whitworth J. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS. 2002;16:597-603. (Pubitemid 34218855)
20. Bezemer D, de Ronde A, Prins M, et al. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther. 2006;11:173-8.
21. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43:406-13. (Pubitemid 40096331)
22. Jayaraman G, Archibald C, Kim J, et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr. 2006;42:86-90. (Pubitemid 43947951)
23. Vercauteren J, Wensing A, van de Vijver D, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009;200:1503-8.
24. Little S, Holte S, Routy J, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94. (Pubitemid 34851830)
25. de Mendoza C, Rodriguez C, Eiros J, et al. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis. 2005;41:227-32.
26. Sagir A, Oette M, Kaiser R, et al. Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother. 2007;60:843-8. (Pubitemid 47434265)
27. Guy R, Gold J, Calleja J, et al. Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis. 2009;9:747-59.
28. Jordan M, Bennett D, Bertagnolio S, Gilks C, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 2008;13(Suppl 2):15-23. (Pubitemid 352019086)
29. Ly N, Recordon-Pinson P, Phoung V, et al. Characterization of mutations in HIV type 1 isolates from 144 Cambodian recently infected patients and pregnant women naive to antiretroviral drugs. AIDS Res Hum Retroviruses. 2005;21:971-6. (Pubitemid 41785786)
30. Yuan Y, Cao X, Liu H, et al. [Study on the transmission of drug resistant human immunodeficiency virus-1 in Henan province]. Zhonghua Yu Fang Yi Xue Za Zhi. 2009;43:956-9.
31. Chen X, Xing H, He J, et al. [Study on the threshold of HIV-1 drug resistance in Hunan province]. Zhonghua Liu Xing Bing Xue Za Zhi. 2008;29:787-9.
32. Zhang J, Kang D, Fu J, et al. Surveillance of transmitted HIV type 1 drug resistance in newly diagnosed HIV type 1-infected patients in Shandong Province, China. AIDS Res Hum Retroviruses. 2010;26:99-103.
33. Liao L, Xing H, Li X, et al. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 isolates from recently infected injecting drug users in western China. AIDS Res Hum Retroviruses. 2007;23:1062-5. (Pubitemid 47492349)
34. Tu Y, Tian F, Yao J, et al. Genotypic drug resistance among recent HIV-1 infected persons in Henan. Chin J AIDS STD. 2009;15:227-9.
35. Wang M, Duan S, Xiang L, et al. [Study on the drug resistance situation among recently infected HIV-1 patients in Dehong]. Zhonghua Liu Xing Bing Xue Za Zhi. 2008;29:905-8.
36. Feng L, Wang M, Han M, Ding X, Jiang Y. [Drug resistance among recent HIV-1 infected men who have sex with men in Chongqing municipality of China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2008;29:455-8.
37. Nguyen H, Duc N, Shrivastava R, et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther. 2008;13(Suppl 2):115-21. (Pubitemid 352019098)
38. Bennett D, Myatt M, Bertagnolio S, Sutherland D, Gilks C. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13(Suppl 2):25-36. (Pubitemid 352019087)
39. Ayouba A, Lien T, Nouhin J, et al. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum Retroviruses. 2009;25:1193-6.
40. Nouhin J, Ngin S, Martin P, et al. Low prevalence of drug resistance transmitted virus in HIV Type 1-infected ARV-naive patients in Cambodia. AIDS Res Hum Retroviruses. 2009;25:543-5.
41. Liao L, Xing H, Shang H, et al. The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr. 2010;53(Suppl 1):S10-4.
42. Si X, Huang H, Wei M, et al. [Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2004;18:308-11.
43. Zhou H, Liao L, Chen X, et al. Genotypic analysis of the pol gene and drug resistance of HIV-1 CRF01-AE, CRF07-BC and subtype B' isolates. Chin J AIDS STD. 2008;14:213-6.
44. Liu J, Yue J, Wu S, Yan Y. Polymorphisms and drug resistance analysis of HIV-1 CRF01-AE strains circulating in Fujian Province, China. Arch Virol. 2007;152:1799-805. (Pubitemid 47498139)
45. Tang Y, Zhan F, Peng G, Chen H, Peng T, Zhu X. Analysis of mutations of drug resistant HIV-1 protease and transcriptase genes in treatment naive patients in Hubei Province. China Tropical Medicine. 2007;7:38.
46. He J, Chen X, Zheng X, et al. Longitudinal survey of antiretroviral drug resistance among untreated HIV-1 infection individuals in Hunan Province. Pract Prev Med. 2007;14:1260-2.
47. Han J, Wang L, Jiang Y, et al. Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China. Int J STD AIDS. 2009;20:249-54.
48. Yao Y, Guo Z, Yang J, et al. Study of HIV-1 drug resistance mutation among antiretroviral treatment-naive patients in Zhejiang Province. Chinese J Health Lab Tech. 2008;18:29-32.
49. Yu G, Li Y, Li J, et al. Genetic diversity and drug resistance of HIV type 1 circulating recombinant Form-BC among drug users in Guangdong Province. AIDS Res Hum Retroviruses. 2009;25:869-75.
50. Yu G, Li J, Diao L, et al. Study on pol gene polymorphism and drug resistance in newly diagnosed HIV-1 infected addicts in Guangdong Province. Chinese J AIDS STD. 2009;15:7-10.
51. Han X, Zhang M, Dai D, et al. [Background study of HIV-1 drug resistant mutations in treatment-naive patients in liaoning province]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006;28:632-6.
52. Tu Y, Wang M, Yao J, et al. HIV-1 genotypic drug resistance among volunteer blood donors in Yunnan, China. Transfusion. 2009;49:1865-73.
53. Tee K, Kamarulzaman A, Ng K. Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. AIDS Res Hum Retroviruses. 2006;22:121-4. (Pubitemid 43277146)
54. Ishizaki A, Cuong N, Thuc P, et al. Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Vietnam. AIDS Res Hum Retroviruses. 2009;25:175-82.
55. Phan T, Ishizaki A, Phung D, Bi X, Oka S, Ichimura H. Characterization of HIV type 1 genotypes and drug resistance mutations among drug-naive HIV type 1-infected patients in Northern Vietnam. AIDS Res Hum Retroviruses. 2010;26:233-5.
56. Lan N, Recordon-Pinson P, Hung P, et al. HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large predominance of CRF01-AE and presence of major resistance mutations to antiretroviral drugs. AIDS Res Hum Retroviruses. 2003;19:925-8. (Pubitemid 37338920)
57. Nerrienet E, Hak C, Ouk V, et al. Low incidence of ARV resistance associated mutations development after 18 months of HAART in an HIV patients cohort in Cambodia. In: 16th International Conference on AIDS. Tonronto, Canada, 2006.
58. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120:e1134-40. (Pubitemid 350085507)
59. Li X-p, Xing H, Wang Z, et al. Study of HIV-1 drug resistance in patients receiving free antiretroviral therapy in China. Virologica Sinica. 2007;22:233-40. (Pubitemid 46995371)
60. Li J, Li H, Liu H, et al. A cohort study of evolving of HIV-1 drug resistance in Henan Province, China. J Microb Infect. 2006;1:211-6.
61. Wang Y, Xing H, Wang Z, et al. Study on influencing factors of emergence of HIV drug resistance in one county of Henan Province. Chin J Pub Hlth. 2007;22.
62. Li J, Li H, Li L, et al. Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res. 2005;15:843-9. (Pubitemid 41826249)
63. Tang H, Zhan F, Chen H, Peng T, Dai Y, Chu X. Monitoring drug resistance among AIDS patients on antiretroviral treatment in Hubei Province. J Pub Hlth Pre Med. 2007;18:26-8.
64. Luo M, Liu H, Zhuang K, et al. Prevalence of drug-resistant HIV-1 in rural areas of Hubei province in the People's Republic of China. J Acquir Immune Defic Syndr. 2009;50:1-8.
65. Li H, Liu W, Liu H, et al. [Study on the antiviral therapy program among people with human immunodeficiency virus in Guangxi Zhuang Authority]. Zhonghua Liu Xing Bing Xue Za Zhi. 2007;28:338-42.
66. Zhang F, Haberer J, Wei H, et al. Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: implications for paediatric treatment in the developing world. Int J STD AIDS. 2009; 20:406-9.
67. Ruan Y, Xing H, Wang X, et al. Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites. Trop Med Int Health. 2010;15:1357-63.
68. Li J, Li H, Li H, et al. Prevalence and evolutionary characteristics of drug resistance HIV strain in Henan Province China. Bull Acad Mil Med Sci. 2005;29:8-12.
69. Li J, Li H, Li L, et al. Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res. 2005;15:843-9. (Pubitemid 41826249)
70. Han X, Dai D, Lu C, et al. Analysis on primary drug resistance of HIV-1 infected man having sex with man. China Public Health. 2007;23:57.